On April 7-10, 2015, a HITAP team visited Dar es Salaam, Tanzania, for a country scoping visit to explore the potential areas for introducing health technology assessment (HTA) to support health resource allocation, focusing on the investment or disinvestment of health technologies. This visit was c

My first trip to India was to participate in a workshop on health technology assessment (HTA) organized by the Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER) and the Health Intervention and Technology Assessment Program (HITAP) in Puducherry, India on 3-5 October 2019.

Achieving universal access to essential healthcare products remains a critical challenge across low- and middle-income countries (LMICs). While individual countries may have made notable strides in strengthening their procurement and regulatory systems, regional disparities in access, affordability,

Evidence-Based Decision-Making in Asia-Pacific with Rapidly Changing Health-Care Systems: Thailand, South Korea, and Taiwan. Thidaporn Jirawattanapisal1 Pritaporn Kingkaew2 Tae-Jin Lee3 Ming-Chin Yang4 1International Health Policy Program, Ministry of Public Health, Muang Nonthaburi,Thailand; 2

(Reuters) – Europe’s medicines regulator, criticised in the past for excessive secrecy, is opening its data vaults to systematic scrutiny in a move that will let independent researchers trawl through millions of pages of clinical trial information.The change is a landmark in transparency that puts E

Since 2013, the HITAP International Unit (HIU) has been providing technical support to various developing countries such as Indonesia, Vietnam, Bhutan, and India by sharing the Thai experience in generating and using health technology assessment (HTA) to inform policy decisions. HITAP works in colla

This cost-utility analysis was conducted as the result of a request from the Subcommittee for Development of the NLEM to provide information on the long-term effectiveness and cost-effectiveness of the screening of osteoporosis and its medical management. This information was then used to inform the Subcommittee regarding the selection of osteoporo

Introduction: The development of new technology to treat patients with metastatic renal cell carcinoma has resulted in promising outcomes in terms of extending life and improving quality of life. In Thailand, where health resources are limited, an economic evaluation of such technology would provide useful information for pricing and reimbursement

Bhutan is a rapidly growing economy that is transitioning from international donor support. As such, the country is looking for ways to ensure that they continue to provide the adequate services and support for their population in a rational and sustainable manner. Bhutan has begun using health tech

Abstract BACKGROUND: Pegylated interferon alpha 2a, alpha 2b and ribavirin have been included to the National List of Essential Medicines (NLEM) for treatment of only chronic hepatitis C genotypes 2 and 3 in Thailand. This reimbursement policy has not covered for other genotypes of hepatitis